Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Gyre Therapeutics (GYRE): Pipeline Progress and Acquisition Integration in Focus

Gyre Therapeutics (GYRE): Pipeline Progress and Acquisition Integration in Focus

Key Takeaways

  • A pending New Drug Application (NDA) for F351 (hydronidone) in chronic hepatitis B-associated liver fibrosis stands as the primary near-term catalyst that could expand Gyre's market reach.
  • The all-stock acquisition of Cullgen adds targeted protein degradation capabilities to Gyre's anti-fibrotic small-molecule focus, broadening the pipeline and strategic options.
  • Full-year 2026 revenue guidance of $100.5 million to $111.0 million remains in place despite acquisition costs and near-term operating losses.
  • Analyst views stay positive overall, with three analysts assigning a "Strong Buy" rating and a 12-month average price target of $18.67, though coverage is still limited.
  • The business faces exposure to regulatory timelines in China and the United States, potential dilution from restructured equity, and risks tied to integrating the new platform.

Strategic Positioning and Market Context

Gyre Therapeutics, Inc. operates as a commercial-stage biopharmaceutical company centered on small-molecule therapies for organ fibrosis and inflammatory diseases. Its position combines a revenue-generating commercial presence in China through ETUARY (pirfenidone), the first approved treatment for idiopathic pulmonary fibrosis (IPF) there, with a late-stage pipeline anchored by F351 (hydronidone). This setup allows commercial products to support development efforts rather than depending entirely on equity raises.

The May 2026 acquisition of Cullgen shifts the company's innovation path by incorporating a targeted protein degradation platform and degrader-antibody conjugates. This move extends Gyre beyond traditional anti-fibrotic chemistry into areas that could reach oncology and additional indications over time. Integration brings execution demands, however, as the combined teams align research approaches while managing a restructured capital structure that includes a new preferred stock class and its implications for dilution and governance.

Key Catalysts on the Horizon

The most prominent upcoming driver remains the pending NDA for F351 (hydronidone) targeting chronic hepatitis B (CHB)-associated liver fibrosis. Approval would broaden the patient base beyond the existing ETUARY franchise and reinforce the core fibrosis approach. A favorable outcome could improve sentiment by turning a pipeline asset into another commercial product, whereas delays might pressure confidence in the overall platform. I also checked this using AI Trend Prediction Engine to review potential directional signals.

Additional readouts from the Cullgen programs in oncology and other areas may provide periodic updates. Leadership has noted plans for investor conferences and ongoing clinical work, pointing to a consistent flow of developments in coming quarters.

Analyst coverage reflects measured optimism. Three analysts from S&P Global maintain a consensus "Strong Buy" with a 12-month average price target of $18.67, ranging from a low of $18 (H.C. Wainwright, reiterated November 2026) to a high of $20 (Noble Financial, reiterated August 2026). The tight range and modest number of analysts suggest alignment among current followers alongside limited broader scrutiny compared with larger biotechs.

Industry Trends and Broader Influences

Gyre sits at the overlap of growing attention to fibrosis as a treatable area and rising activity in targeted protein degradation. The fibrosis market offers appeal due to sizable, historically underserved populations in conditions such as IPF, CHB-associated liver fibrosis, and metabolic dysfunction-associated steatohepatitis (MASH). Regulatory standards in China and the United States represent a variable, as shifts in review processes or pricing could affect the value of new products.

Macro factors influence the company mainly through capital access. As a small-cap developer with ongoing cash needs, Gyre's financing options respond to interest-rate environments and investor appetite for biotech risk. A low-leverage balance sheet offers some buffer, yet persistent losses keep financing and dilution management central to the outlook.

2026 Outlook and Longer-Term Considerations

Looking ahead, Gyre's path centers on execution. The pivotal factor is whether F351 (hydronidone) gains approval and how rapidly the company can translate that into commercial sales within a competitive Chinese market. Success would aid the shift from a single-product fibrosis business toward a wider platform.

Further themes include progress on Cullgen programs, maintenance of gross margins in commercial operations, and absorption of acquisition-related costs. Competition from larger players in fibrosis and protein degradation remains relevant, as does the possibility of additional equity activity. Consensus estimates anticipate revenue growth in 2027, based on expectations that new products and pipeline advances will eventually balance current spending, though these views hinge on unresolved clinical and regulatory results.

AI Tools Supporting My Research Process

In reviewing names like this, I periodically reference Tickeron’s AI Trend Prediction Engine to help frame potential short-term directional trends alongside fundamental catalysts. The tool supplies searchable forecasts, historical context, and alerts that add structure when monitoring regulatory and pipeline updates for a development-stage company.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GYRE

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


GYRE's RSI Indicator ascends from oversold territory

The RSI Indicator for GYRE moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 40 similar instances when the indicator left oversold territory. In 39 of the 40 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where GYRE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on GYRE as a result. In 78 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for GYRE just turned positive on November 17, 2026. Looking at past instances where GYRE's MACD turned positive, the stock continued to rise in 41 of 43 cases over the following month. The odds of a continued upward trend are 90%.

Following a +5.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 216 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

GYRE moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for GYRE entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.676) is normal, around the industry mean (3.592). P/E Ratio (-23.800) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
12770 High Bluff Drive
Phone
+1 858 567-7770
Employees
625
Web
https://www.gyretx.com
Interact to see
Advertisement
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
NVIDIA reported revenue of $115.84 billion for the third quarter of fiscal 2027, up 103% year over year and ahead of both company guidance and consensus estimates. Non-GAAP earnings per share (EPS, a measure of profit per outstanding share) came in at $2.68 , beating the roughly $2.47 analysts had expected.